Innovent Biologics and Pfizer in $10.5B deal for 12 cancer drug trials
Chinese biotech gets $650M upfront and up to $9.85B in milestones from Pfizer.
Innovent Biologics, a Hong Kong-listed Chinese biopharmaceutical company based in Suzhou, has announced a landmark collaboration with Pfizer valued at up to $10.5 billion. The deal involves 12 oncology programs, including eight early-stage assets originated by Innovent and four discovery programs proposed by Pfizer. Innovent will receive an upfront payment of $650 million and is eligible for up to $9.85 billion in development, regulatory, and commercial milestone payments, plus double-digit royalties on approved products.
Under the agreement, Innovent will lead Phase 1 clinical trials for all 12 programs, after which Pfizer will take over global development. For four of the programs, the companies will jointly develop and co-commercialize selected assets in the United States and Europe, while Innovent retains all rights in China. This structure allows Pfizer to expand its oncology pipeline with promising Chinese assets while giving Innovent access to Pfizer’s global development and commercialization infrastructure.
- Deal covers 12 oncology programs: 8 early-stage assets from Innovent, 4 discovery programs from Pfizer.
- Innovent receives $650M upfront, up to $9.85B in milestones, plus double-digit royalties on approved products.
- Innovent leads Phase 1 for all programs; Pfizer leads global development. Four programs co-commercialized in US/Europe.
Why It Matters
This deal signals growing cross-border pharma collaboration and validates Chinese biotech innovation on a global scale.